regulatory approval

Oklo stock surged 160% but fell 65% from peaks, despite zero revenue and $9.7B valuation. Meta deal looks promising, but regulatory delays and execution risks make it a risky bet.

Suntex Enterprises to distribute shares to Golden Triangle Ventures shareholders at 30:1 ratio pending regulatory approval, advancing acquisition discussions in infrastructure and construction sectors.

Argenx's Vyvgart gains momentum with Japan approval and Fujifilm partnership, positioning the FcRn inhibitor for significant market expansion across multiple autoimmune indications through 2030.

Crédit Agricole Ukraine agreed to acquire up to 100% of Bank Lviv, strengthening its western Ukraine presence in SME and agricultural banking through mid-2026.

Freedom Holding ($FRHC) agrees to acquire 99.32% of Turkish Bank A.Ş., gaining entry to Turkey's 90 million-person banking market as part of international expansion strategy.

TMC receives positive NOAA feedback for deep-seabed mining application but remains unprofitable with substantial regulatory and operational risks. Suitable only for aggressive investors.

BridgeBio Pharma jumps 12.6% after William Blair initiates coverage with Outperform rating, citing accelerating product launches and robust rare-disease pipeline.

Hapag-Lloyd to acquire ZIM for $35/share all-cash. Stock trades ~$28, offering 25% upside. Israel's Golden Share concerns addressed via independent vessel operation.

Abecma CAR-T therapy market surging on rising myeloma cases and regulatory wins. BMS-backed treatment faces headwinds from tariffs but eyes earlier-line expansion.

Netflix scrapped its $72B Warner Bros. acquisition, securing $2.8B termination fee and preserving capital for core streaming operations amid regulatory scrutiny.

Uber and Joby Aviation partner on air taxi services launching in 2026, though viability questions persist amid high costs and regulatory hurdles.

WBD CEO David Zaslav sold $114.1M in stock following strong 147.9% gains. Paramount-Skydance merger on track for Q3 2026 close, positioning him for billionaire status.

Nxera Pharma seeks South Korean approval for insomnia drug daridorexant, already marketed globally, with expected 2027 regulatory decision.

Quipt Home Medical shareholders voted 98.9% in favor of acquisition by Kingswood and Forager Capital for US$3.65 per share, with court approval expected March 5, 2026.

Ziff Davis stock surges 73% after agreeing to sell Connectivity division to Accenture for $1.2B in cash, with proceeds directed toward debt reduction and corporate purposes.

NuScale's regulatory monopoly in U.S. SMR market positions it uniquely to serve AI data centers' 24/7 power needs, with $1.3B cash buffer and TVA contract potential ahead despite Q4 earnings miss.

TransMedics expands organ preservation technology platform and invests in dedicated aircraft transportation to improve transplant logistics and organ utilization rates.

Aquarian Capital to acquire Brighthouse Financial for $70/share, offering 12% upside but carrying regulatory and execution risks through 2026 closing.

Archer Aviation's profitability depends on 2026 FAA certification of its eVTOL aircraft. The company has $1.6B cash but faces regulatory uncertainty risks.

Draganfly raises $50M through registered direct offering at $7 per share. Funds will support product development, R&D, and potential strategic acquisitions.